| scholarly article | Q13442814 |
| P2093 | author name string | Chunling Zhao | |
| Dianbao Zhang | |||
| Xianfen Zhang | |||
| P2860 | cites work | Prediction of venous thromboembolism in cancer patients. | Q51662626 |
| Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. | Q53058565 | ||
| Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. | Q53124033 | ||
| Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. | Q54410290 | ||
| Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. | Q54616228 | ||
| Prognosis of Cancers Associated with Venous Thromboembolism | Q57301047 | ||
| Anti-angiogenesis: new concept for therapy of solid tumors | Q70493357 | ||
| Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy | Q79825413 | ||
| Heterogeneity testing in meta-analysis of genome searches | Q81128804 | ||
| Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes | Q82656539 | ||
| Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) | Q83523403 | ||
| Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer | Q86121541 | ||
| Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies | Q86776509 | ||
| Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis | Q27026453 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family | Q28199597 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells | Q28249984 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Role of angiogenesis in tumor growth and metastasis | Q29614309 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data | Q30926358 | ||
| A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). | Q33408559 | ||
| PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s | Q33418542 | ||
| Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer | Q33418595 | ||
| Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer | Q33598561 | ||
| Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis | Q33904867 | ||
| Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial | Q34050239 | ||
| Bevacizumab increases risk for severe proteinuria in cancer patients | Q34124173 | ||
| International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. | Q34285538 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials | Q34554398 | ||
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Q34658812 | ||
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | Q34662482 | ||
| Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials | Q34900938 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications | Q35040017 | ||
| The role of hydrogen peroxide in endothelial proliferative responses | Q35062078 | ||
| Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis | Q35118673 | ||
| Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization | Q35753569 | ||
| Mechanisms of adverse effects of anti-VEGF therapy for cancer | Q36609627 | ||
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 | ||
| Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials | Q36729895 | ||
| Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | Q37692420 | ||
| Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis | Q37698956 | ||
| Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37721064 | ||
| Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis | Q37807240 | ||
| Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials | Q38073936 | ||
| Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis | Q38158401 | ||
| Regulation of vascular function on posttranscriptional level. | Q38167316 | ||
| Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. | Q38184936 | ||
| The role of tissue factor isoforms in cancer biology. | Q38210094 | ||
| Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis | Q38216142 | ||
| Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups | Q38237318 | ||
| Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Q38245038 | ||
| Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors | Q38313896 | ||
| Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. | Q39514813 | ||
| Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer | Q39576387 | ||
| Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells | Q39578556 | ||
| Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials | Q41650735 | ||
| Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer | Q42631933 | ||
| Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer | Q42632045 | ||
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. | Q43138109 | ||
| Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors | Q43213739 | ||
| Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups | Q43497234 | ||
| Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies | Q43559046 | ||
| Congestive heart failure risk in patients with breast cancer treated with bevacizumab. | Q44082273 | ||
| Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis | Q44391184 | ||
| Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial | Q46684151 | ||
| Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer | Q46972019 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thromboembolism | Q891391 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 3695-3704 | |
| P577 | publication date | 2016-06-21 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review | |
| P478 | volume | 9 |
| Q47837536 | Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis | cites work | P2860 |
Search more.